LY 221068

Drug Profile

LY 221068

Latest Information Update: 07 Jun 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Anti-inflammatories; Small molecules; Thiazolidines
  • Mechanism of Action Lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Rheumatic disorders

Most Recent Events

  • 07 Jun 2001 No-Development-Reported for Rheumatic disorders in USA (PO)
  • 04 May 1995 Two new in vivo studies have been added to the pharmacodynamics section ,.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top